MX2021006809A - Rutas lineales en fase de solucion para hexapeptidos de wnt. - Google Patents

Rutas lineales en fase de solucion para hexapeptidos de wnt.

Info

Publication number
MX2021006809A
MX2021006809A MX2021006809A MX2021006809A MX2021006809A MX 2021006809 A MX2021006809 A MX 2021006809A MX 2021006809 A MX2021006809 A MX 2021006809A MX 2021006809 A MX2021006809 A MX 2021006809A MX 2021006809 A MX2021006809 A MX 2021006809A
Authority
MX
Mexico
Prior art keywords
wnt
hexapeptides
solution phase
linear solution
phase routes
Prior art date
Application number
MX2021006809A
Other languages
English (en)
Inventor
Pratap Tadikonda Veerabhadra
Rao Kamaraju Raghavendra
Dennis Henriksen
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of MX2021006809A publication Critical patent/MX2021006809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere, en general, al campo de la síntesis de polipéptidos y más particularmente, a una síntesis lineal en fase de solución del hexapéptido de Wnt Foxy-5 y a derivados protegidos y fragmentos peptídicos del mismo.
MX2021006809A 2018-12-14 2019-12-02 Rutas lineales en fase de solucion para hexapeptidos de wnt. MX2021006809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212658.1A EP3666789A1 (en) 2018-12-14 2018-12-14 Linear solution phase routes for wnt hexapeptides
PCT/EP2019/083309 WO2020120198A1 (en) 2018-12-14 2019-12-02 Linear solution phase routes for wnt hexapeptides

Publications (1)

Publication Number Publication Date
MX2021006809A true MX2021006809A (es) 2021-08-24

Family

ID=65010407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006809A MX2021006809A (es) 2018-12-14 2019-12-02 Rutas lineales en fase de solucion para hexapeptidos de wnt.

Country Status (17)

Country Link
US (1) US20220017568A1 (es)
EP (2) EP3666789A1 (es)
JP (1) JP7362148B2 (es)
KR (1) KR20210112331A (es)
CN (1) CN113646324B (es)
AU (1) AU2019395708A1 (es)
BR (1) BR112021011318A2 (es)
CA (1) CA3123331C (es)
CL (1) CL2021001532A1 (es)
DK (1) DK3894426T3 (es)
ES (1) ES2934161T3 (es)
FI (1) FI3894426T3 (es)
HU (1) HUE061310T2 (es)
MX (1) MX2021006809A (es)
PL (1) PL3894426T3 (es)
SG (1) SG11202105965PA (es)
WO (1) WO2020120198A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4176901T3 (pl) 2021-12-10 2024-04-08 Wntresearch Ab Stabilne kompozycje heksapeptydu foxy-5 o wysokiej rozpuszczalności zawierające zasadę azotową

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530263T3 (es) 2005-05-30 2015-02-27 Wntresearch Ab Un ligando peptídico para alterar la migración de células cancerígenas
RU2010147806A (ru) * 2008-04-30 2012-06-10 Внтрисерч Аб (Se) Восстановление активности a-рецептора эстрогена
CN102105162B (zh) * 2008-08-13 2014-05-07 温特研究公司 Wnt5-α肽衍生物用于治疗黑色素瘤和胃癌的用途
JP6921755B2 (ja) * 2014-12-10 2021-08-18 ハイパーステム ソシエテ アノニム 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
CN105111303B (zh) * 2015-06-23 2019-07-26 济南康和医药科技有限公司 一种固液结合制备利拉鲁肽的方法
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides

Also Published As

Publication number Publication date
EP3894426A1 (en) 2021-10-20
EP3666789A1 (en) 2020-06-17
JP7362148B2 (ja) 2023-10-17
WO2020120198A1 (en) 2020-06-18
PL3894426T3 (pl) 2023-03-13
SG11202105965PA (en) 2021-07-29
WO2020120198A8 (en) 2021-10-28
CA3123331C (en) 2023-12-05
CN113646324B (zh) 2024-03-29
US20220017568A1 (en) 2022-01-20
DK3894426T3 (da) 2022-12-19
JP2022513474A (ja) 2022-02-08
CA3123331A1 (en) 2020-06-18
FI3894426T3 (fi) 2023-01-13
EP3894426B1 (en) 2022-09-21
HUE061310T2 (hu) 2023-06-28
KR20210112331A (ko) 2021-09-14
AU2019395708A1 (en) 2021-06-24
ES2934161T3 (es) 2023-02-17
CL2021001532A1 (es) 2021-12-31
CN113646324A (zh) 2021-11-12
BR112021011318A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
ECSP18082207A (es) Neoantígenos y métodos de su uso
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
UA118167C2 (uk) Пептид та його застосування
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
SA518400462B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2022000252A (es) Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
EP3450449A3 (en) Peptide compositions
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
SG10201805039UA (en) Protease resistant peptides
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
MX2018008019A (es) Etiqueta de peptido y proteina etiquetada que incluye la misma.
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2019004116A (es) Metodo de preparacion de peptidos que comprenden una cadena lateral de lisina modificada lipofilicamente.
MX2019013362A (es) PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA.
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
MX2021006809A (es) Rutas lineales en fase de solucion para hexapeptidos de wnt.
PH12021551055A1 (en) Klk5 inhibitory peptide
MX2018014490A (es) Peptido antimicrobiano modificado derivado de un dominio rico en arginina.
NZ744289A (en) Composition containing amino acids